Enzymotec Ltd., an Israeli developer of lipid-based biofunctional ingredients, has raised $11 million in Series B-1 funding. Arancia International Inc. was joined by return backers Galam Ltd., Ofer Hi-Tech Investments Ltd. and Millennium II Materials Technology Fund. Enzymotec also is finalizing a new $7 million line of credit from an undisclosed Israeli bank.
